F10 and Portal vein thrombosis: Patients (≥18 years old) who received andexanet alfa for the reversal of oral FXa inhibitor-associated extracranial hemorrhage, N=21, male: 13/21 (61.9%), female: 8/21 (38.1%), age (mean ± SD) 73.2 ± 15.4; indication for anticoagulation: Afib 16/21, recurrent popliteal thrombosis post-bypass 1, renal thrombosis 1, recurrent DVT 1, portal vein thrombosis 1, SVC occlusion 1; FXa inhibitor: apixaban 14, rivaroxaban 7